title: Enzyme replacement therapy in Japanese Fabry disease patients: the results of a phase 2 bridging study.
abstract: Fabry Disease (alpha-galactosidase A deficiency) is an X-linked hereditary disorder leading to the pathological accumulation of globotriaosylceramide (GL-3) in lysosomes, particularly in the vascular endothelium of the kidney, heart and brain. We report the results of an open-label phase 2 study that was undertaken to evaluate whether ethnic differences exist that would affect agalsidase beta (Fabrazyme) treatment of Fabry patients in the Japanese population, relative to safety and efficacy. The study design mirrored the design of the completed phase 3 clinical trial that led to approval of the product agalsidase beta. The 13 Japanese, male Fabry patients enrolled in the study received the enzyme replacement therapy over a period of 20 weeks as biweekly infusions. All selected efficacy end points showed improvements that were comparable with findings from the phase 3 study. These improvements included reductions of GL-3 accumulation in both kidney and skin capillary endothelial cells to (near) normal levels (92% of patients). Kidney and plasma GL-3 levels decreased by 51.9% and 100%, respectively, by ELISA. Renal function remained normal. Fabry-associated pain, and quality of life, showed improvement over baseline in multiple categories. Related adverse events were mild or moderate in intensity and mostly infusion-associated (fever and rigors). As expected, IgG antibody formation was observed in 85% of the patients, but had no effect on treatment response. These results suggest that treatment with agalsidase beta is safe and effective in Japanese patients with Fabry disease. With regard to safety and efficacy, no differences were observed as compared to the caucasian population.
authors.affiliation: Tokyo Jikei University School of Medicine, Tokyo and Chubu National Hospital, Japan. yosh@sepia.ocn.ne.jp
authors.forename: Y
authors.initials: Y
authors.lastname: Eto
authors.forename: T
authors.initials: T
authors.lastname: Ohashi
authors.forename: Y
authors.initials: Y
authors.lastname: Utsunomiya
authors.forename: M
authors.initials: M
authors.lastname: Fujiwara
authors.forename: A
authors.initials: A
authors.lastname: Mizuno
authors.forename: K
authors.initials: K
authors.lastname: Inui
authors.forename: N
authors.initials: N
authors.lastname: Sakai
authors.forename: T
authors.initials: T
authors.lastname: Kitagawa
authors.forename: Y
authors.initials: Y
authors.lastname: Suzuki
authors.forename: S
authors.initials: S
authors.lastname: Mochizuki
authors.forename: M
authors.initials: M
authors.lastname: Kawakami
authors.forename: T
authors.initials: T
authors.lastname: Hosoya
authors.forename: M
authors.initials: M
authors.lastname: Owada
authors.forename: H
authors.initials: H
authors.lastname: Sakuraba
authors.forename: H
authors.initials: H
authors.lastname: Saito
mesh_terms: D000328:Adult; D003404:Creatinine / Q000378:metabolism; D004797:Enzyme-Linked Immunosorbent Assay; D000795:Fabry Disease / Q000188:drug therapy*; D006801:Humans; D007074:Immunoglobulin G / Q000378:metabolism; D007527:Isoenzymes / Q000494:pharmacology*; D007564:Japan; D007668:Kidney / Q000378:metabolism; D008297:Male; D008657:Metabolic Clearance Rate; D009206:Myocardium / Q000378:metabolism; D012449:Safety; D012867:Skin / Q000378:metabolism; D016896:Treatment Outcome; D014281:Trihexosylceramides / Q000097:blood; D000519:alpha-Galactosidase / Q000494:pharmacology*
chemical_list: D007074:Immunoglobulin G; D007527:Isoenzymes; D014281:Trihexosylceramides; C018549:globotriaosylceramide; D003404:Creatinine; D000519:alpha-Galactosidase; C459420:agalsidase beta